AstraZeneca PLC (NASDAQ:AZN) Stock Position Raised by Kolinsky Wealth Management LLC

Kolinsky Wealth Management LLC lifted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 11.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,052 shares of the company’s stock after buying an additional 400 shares during the period. Kolinsky Wealth Management LLC’s holdings in AstraZeneca were worth $316,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. McClarren Financial Advisors Inc. grew its position in AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after purchasing an additional 247 shares during the last quarter. GHP Investment Advisors Inc. bought a new position in AstraZeneca in the 2nd quarter worth about $26,000. Capital Performance Advisors LLP bought a new position in AstraZeneca in the 3rd quarter worth about $28,000. Pathway Financial Advisers LLC bought a new position in AstraZeneca in the 1st quarter worth about $29,000. Finally, CANADA LIFE ASSURANCE Co lifted its stake in shares of AstraZeneca by 40.6% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after acquiring an additional 146 shares during the period. Institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on AZN shares. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Finally, TD Cowen increased their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, AstraZeneca currently has a consensus rating of “Moderate Buy” and a consensus price target of $89.75.

AstraZeneca Trading Up 0.6 %

AstraZeneca stock opened at $67.62 on Friday. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The firm has a market capitalization of $209.66 billion, a price-to-earnings ratio of 32.35, a P/E/G ratio of 1.23 and a beta of 0.47. The company has a 50 day moving average price of $72.27 and a 200 day moving average price of $77.43.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the prior year, the firm earned $0.87 EPS. The company’s revenue was up 18.0% compared to the same quarter last year. Research analysts forecast that AstraZeneca PLC will post 4.1 EPS for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.